Gene editing therapy ready for cardiovascular diseases: opportunities, challenges, and perspectives

Gene editing nucleases (GENs), represented by CRISPR/Cas9, have become major tools in biomedical research and offer potential cures for many human diseases. Gene editing therapy (GETx) studies in animal models targeting genes such as proprotein convertase subtilisin/kexin type 9 (PCSK9), apolipoprot...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jun, Ren, Zhuoying, Xu, Jie, Zhang, Jifeng, Chen, Y. Eugene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter 2021
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471110/
https://www.ncbi.nlm.nih.gov/pubmed/37724071
http://dx.doi.org/10.1515/mr-2021-0010
_version_ 1785099808067813376
author Zhou, Jun
Ren, Zhuoying
Xu, Jie
Zhang, Jifeng
Chen, Y. Eugene
author_facet Zhou, Jun
Ren, Zhuoying
Xu, Jie
Zhang, Jifeng
Chen, Y. Eugene
author_sort Zhou, Jun
collection PubMed
description Gene editing nucleases (GENs), represented by CRISPR/Cas9, have become major tools in biomedical research and offer potential cures for many human diseases. Gene editing therapy (GETx) studies in animal models targeting genes such as proprotein convertase subtilisin/kexin type 9 (PCSK9), apolipoprotein C3 (APOC3), angiopoietin Like 3 (ANGPTL3) and inducible degrader of the low-density lipoprotein receptor (IDOL) have demonstrated the benefits and advantages of GETx in managing atherosclerosis. Here we present our views on this brand new therapeutic option for cardiovascular diseases (CVD).
format Online
Article
Text
id pubmed-10471110
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher De Gruyter
record_format MEDLINE/PubMed
spelling pubmed-104711102023-09-18 Gene editing therapy ready for cardiovascular diseases: opportunities, challenges, and perspectives Zhou, Jun Ren, Zhuoying Xu, Jie Zhang, Jifeng Chen, Y. Eugene Med Rev (Berl) Perspective Gene editing nucleases (GENs), represented by CRISPR/Cas9, have become major tools in biomedical research and offer potential cures for many human diseases. Gene editing therapy (GETx) studies in animal models targeting genes such as proprotein convertase subtilisin/kexin type 9 (PCSK9), apolipoprotein C3 (APOC3), angiopoietin Like 3 (ANGPTL3) and inducible degrader of the low-density lipoprotein receptor (IDOL) have demonstrated the benefits and advantages of GETx in managing atherosclerosis. Here we present our views on this brand new therapeutic option for cardiovascular diseases (CVD). De Gruyter 2021-10-21 /pmc/articles/PMC10471110/ /pubmed/37724071 http://dx.doi.org/10.1515/mr-2021-0010 Text en © 2021 Jun Zhou et al., published by De Gruyter, Berlin/Boston https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
spellingShingle Perspective
Zhou, Jun
Ren, Zhuoying
Xu, Jie
Zhang, Jifeng
Chen, Y. Eugene
Gene editing therapy ready for cardiovascular diseases: opportunities, challenges, and perspectives
title Gene editing therapy ready for cardiovascular diseases: opportunities, challenges, and perspectives
title_full Gene editing therapy ready for cardiovascular diseases: opportunities, challenges, and perspectives
title_fullStr Gene editing therapy ready for cardiovascular diseases: opportunities, challenges, and perspectives
title_full_unstemmed Gene editing therapy ready for cardiovascular diseases: opportunities, challenges, and perspectives
title_short Gene editing therapy ready for cardiovascular diseases: opportunities, challenges, and perspectives
title_sort gene editing therapy ready for cardiovascular diseases: opportunities, challenges, and perspectives
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471110/
https://www.ncbi.nlm.nih.gov/pubmed/37724071
http://dx.doi.org/10.1515/mr-2021-0010
work_keys_str_mv AT zhoujun geneeditingtherapyreadyforcardiovasculardiseasesopportunitieschallengesandperspectives
AT renzhuoying geneeditingtherapyreadyforcardiovasculardiseasesopportunitieschallengesandperspectives
AT xujie geneeditingtherapyreadyforcardiovasculardiseasesopportunitieschallengesandperspectives
AT zhangjifeng geneeditingtherapyreadyforcardiovasculardiseasesopportunitieschallengesandperspectives
AT chenyeugene geneeditingtherapyreadyforcardiovasculardiseasesopportunitieschallengesandperspectives

Ejemplares similares